Tech Company Financing Transactions
Grit Biotechnology Funding Round
Grit Biotechnology, operating out of Zhuhai, Guangdon, secured $60 million in investment from CICC Capital, Decheng Capital and HeFangTian Venture Partnership.
Transaction Overview
Company Name
Announced On
9/8/2023
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support its Tumor-Infiltrating Lymphocyte (TIL) pipeline development, including the pivotal Phase II trial for GT101 and the advancement of gene-edited TIL products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Room 110-431, Building 18, Creative Valley, No. 1889 Huandao
Zhuhai, Guangdon, Undisclosed
CN
Zhuhai, Guangdon, Undisclosed
CN
Phone
Undisclosed
Website
Email Address
Overview
Grit Bio is a Chinese cell therapy company founded in 2019. The company is developing tumor-infiltrating lymphocyte (TIL) therapy program to address the unmet medical needs and to improve the quality of life for patients with solid tumor. GT101 - Grit's non-gene-modified TIL product manufactured using proprietary process - is the first TIL product received Investigational New Drug (IND) approval in China and is currently in Phase 1 clinical trial.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yarong Liu
Browse more venture capital transactions:
Prev: 9/8/2023: Brine Fi venture capital transaction
Next: 9/8/2023: GoCharlie venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs